US Clinical Trial Stocks Surge Over $10 Billion in Market Cap in One Day

ICON PLC (Nasdaq: ICLR) closed at $121 on the 5th, up 8.06% on the day. Trading volume reached 1,196,911 shares, and the company’s market capitalization jumped by roughly $810 million—about ₩1.2 trillion—in a single session, bringing its total market value to approximately $9.3 billion (around ₩13.5 trillion).

The company recently announced that its board audit committee has completed an internal review of its accounting practices and determined that revenue for 2023, 2024, and the third quarter of 2025 had been overstated by less than 2% compared with prior disclosures. As a result, ICON plans to restate all affected financial statements. The company emphasized that the investigation found no impact on customers, operations, or cash flow. ICON has filed a Form 6-K with the U.S. Securities and Exchange Commission, noting that financial statements issued since 2023 should no longer be relied upon, and is now working to resolve the accounting matter.

Headquartered in Dublin, Ireland, ICON is a global contract research organization (CRO) that designs and conducts clinical trials on behalf of pharmaceutical, biotech, and medical-device companies, as well as government and public-health agencies, under a fee-for-service model. Fueled by increased outsourcing of clinical studies after the COVID-19 pandemic, ICON rose into the top tier of the CRO industry. However, recent accounting issues and stock volatility have put financial transparency squarely in investors’ sights.